Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

Humans have appreciated the beauty of flowers for centuries. Yet, flowers aren't just aesthetically pleasing. They also play ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...

Cell and gene therapy tout promising results, but manufacturing challenges around personalized treatments require industry ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...